--- title: "Novocure | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 174.06 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/284753306.md" datetime: "2026-04-30T11:03:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284753306.md) - [en](https://longbridge.com/en/news/284753306.md) - [zh-HK](https://longbridge.com/zh-HK/news/284753306.md) --- # Novocure | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 174.06 M Revenue: As of FY2026 Q1, the actual value is USD 174.06 M, beating the estimate of USD 167.77 M. EPS: As of FY2026 Q1, the actual value is USD -0.62, missing the estimate of USD -0.5129. EBIT: As of FY2026 Q1, the actual value is USD -67.42 M. #### Net Revenues NovoCure Limited reported total net revenues of $174,055 thousand for the first quarter ended March 31, 2026, marking a 12% increase compared to the same period in 2025, primarily driven by active patient growth in European markets . The U.S. contributed $96.0 million, Germany $24.5 million, France $22.9 million, and Japan $10.2 million . Other active markets generated $15.7 million . Net revenue from Germany included a one-time benefit of $2.5 million, while France benefited from contract performance improvements, including a one-time benefit of $1 million . Revenue from NovoCure Limited’s partnership with Zai Lab in Greater China totaled $4.8 million . Recognized revenue from Optune Lua® was $3.1 million for the quarter . #### Gross Margin Gross margin for the quarter was 78%, an increase from 75% in the prior year, mainly due to lower array costs from improved array utilization and reduced supplier prices . #### Operating Costs and Expenses - **Research, Development and Clinical Studies**: Expenses were $58,336 thousand, an 8% increase from the same period in 2025, primarily due to increased costs for patient recruitment in the Phase 3 KEYNOTE D58 clinical trial . - **Sales and Marketing**: Expenses were $58,357 thousand, up 5% compared to the same period in 2025, driven by costs related to the launch of Optune Pax® in the U.S. and Optune Lua in Japan . - **General and Administrative**: Expenses significantly increased by 92% to $85,853 thousand, mainly due to a $43 million share-based compensation expense triggered by the U.S. FDA approval of Optune Pax . #### Operating Income (Loss) Operating loss for the quarter was - $67,420 thousand, compared to - $37,865 thousand in the first quarter of 2025 . #### Financial Income (Expenses), Net Financial income (expenses), net was - $1,838 thousand for the quarter, compared to $7,570 thousand in the first quarter of 2025 . #### Income (Loss) Before Income Tax Income (loss) before income tax was - $69,258 thousand for the quarter, compared to - $30,295 thousand in the first quarter of 2025 . #### Income Tax Income tax was $1,880 thousand for the quarter, compared to $4,024 thousand in the first quarter of 2025 . #### Net Loss NovoCure Limited reported a net loss of - $71,138 thousand for the quarter . #### Adjusted EBITDA Adjusted EBITDA for the quarter was - $287 thousand, a significant improvement from - $4,988 thousand in the prior year . #### Cash and Investments Cash, cash equivalents, and short-term investments totaled $432.0 million as of March 31, 2026 . #### Active Patients (Operational Metric) As of March 31, 2026, there were 4,791 total active patients globally on TTFields therapy . Optune Gio had 4,543 active patients, an increase of 9% from the same period in 2025, with 2,250 in the U.S., 641 in Germany, 503 in France, 535 in Japan, and 614 in other active markets . Optune Lua had 165 active patients, a 56% increase from the same period in 2025, including 106 in the U.S., 47 in Germany, 2 in France, 6 in Japan, and 4 in other active markets . Optune Pax had 83 active patients in the U.S., and the company received 169 prescriptions for Optune Pax during the quarter . #### 2026 Financial Guidance (Outlook) NovoCure Limited updated its full-year 2026 guidance, projecting total net revenue between $690 million and $710 million, and Adjusted EBITDA between - $15 million and $0 million . This guidance assumes mid-single digit net revenue growth from Optune Gio, and a collective net revenue contribution from Optune Lua and Optune Pax of $15 million to $25 million . It also anticipates a gross margin in the mid-70s percent, based on foreign exchange rates as of March 31, 2026 . ### Related Stocks - [NVCR.US](https://longbridge.com/en/quote/NVCR.US.md) ## Related News & Research - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Halliburton declares 2026 Q2 dividend of $0.17 a share](https://longbridge.com/en/news/287276574.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)